Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9685806 | 0.84 | MAOA (0.46) | ALDH1A1MAOBMAPT | |
| SCHEMBL9684974 | 0.84 | MAOA (0.46) | ALDH1A1MAOBMAPT | |
| SCHEMBL15618793 | 0.82 | ALDH1A1 (0.55) | ALDH1A1HTTHTR2ARAB9AMAOB | |
| SCHEMBL991790 | 0.79 | ALDH1A1 (0.52) | ALDH1A1HTTHTR2ARAB9AMAOB | |
| SCHEMBL14415498 | 0.79 | ALDH1A1 (0.52) | ALDH1A1HTTHTR2ARAB9AMAOB | |
| SCHEMBL991365 | 0.79 | KCNH2 (0.50) | KCNH2HTR2AMAOBMAPT | |
| SCHEMBL23199292 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KCNH2HTTHTR2ARAB9A | |
| SCHEMBL15618795 | 0.78 | ALDH1A1 (0.51) | ALDH1A1HTTHTR2ARAB9AMAOB | |
| SCHEMBL13684200 | 0.76 | ALDH1A1 (0.54) | ALDH1A1HTTHTR2ARAB9AMAOB | |
| SCHEMBL991664 | 0.75 | KCNH2 (0.49) | KCNH2HTR2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011140009-A1 | METHODS OF USING SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2373694-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BioMarin Pharmaceutical Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | SI, FUT6, B3GAT3 | ALDH1A1 3289/4885KCNH2 979/4885HTT 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.